Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...
hemophilianewstoday23h
After 4 years, hemophilia B bleeding rates remain low with Hemgenix
Four years after receiving Hemgenix in a Phase 3 trial, bleeding rates and the use of replacement therapy are low for men ...
ICON, a pioneer in the 3D printing of homes, raises $56M led by Norwest, Tiger Global
ICON, which builds homes using 3D printing, has closed on $56 million in Series C funding co-led by Norwest Venture Partners ...
IN8bio reports promising phase 1 results for leukemia therapy
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
FierceBiotech1d
Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences
The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality ...
Phase raises $13M to speed up the UX design process with its no-code platform
UX and UI designers work closely with engineers throughout product development to build and implement design concepts and ...
UroToday1d
ASCO GU 2025: Gene Signature Predictor of Dose-response to Prostate Radiation: Validation of PORTOS in Phase III Trials
In the post-op SAKK 09/10 trial, only patients in the higher PORTOS score group benefited from radiation therapy dose escalation (clinical progression free survival HR 0.19, 95% CI 0.05-0.70; p = 0.01 ...